HOXA9 and leukemia: There were also significantly fewer Mac1+Gr1− leukemia cells in Hoxa9/IRX3 recipients and, on average, double the percentage of cells positive for the stem and progenitor marker KIT (Figure 3J), although in view of heterogeneous levels of expression, this difference did not reach statistical significance.